How we—you and T1D Exchange—played a role in advancing intranasal glucagon
We want to congratulate two of our member companies, Lilly and Locemia Solutions, on some exciting news!
Lilly has acquired Phase III Intranasal Glucagon from Locemia Solutions. Intranasal glucagon is a potential treatment for severe hypoglycemia in people with diabetes who use insulin and could be the first needle-free rescue treatment for severe hypoglycemia. (Learn more about severe hypoglycemia and intranasal glucagon below.)
This announcement highlights the important collaborations that are happening every day to improve outcomes in type 1 diabetes.
And you are part of this exciting collaboration. How? Our T1D Exchange community participated in advancing intranasal glucagon in the following ways:
Question of the Day
- In 2013, the Glu community answered a Question of the Day about the complexities of using injectable rescue glucagon and about severe hypoglycemia preparedness. Our community’s real-world experiences helped Locemia Solutions define the challenges of injectable glucagon in discussions with the FDA, which ultimately led to clinical studies of an intranasal form of glucagon.
T1D Exchange Clinic Expertise
- Locemia Solutions partnered with T1D Exchange to:
- Design clinical protocols and conduct two multi-site clinical studies. Our highly qualified clinical investigators conducted these studies.
- Recruit participants from the T1D Exchange Clinic Registry to participate in clinical studies.
“When you’re looking for that special population of people with diabetes, access to the expertise, and the investigators who can run the special procedures like that, T1D Exchange offers something that just is unavailable anywhere [else] in the world…” —Dr. Claude Piché, CEO of Locemia Solutions
- Design clinical protocols and conduct two multi-site clinical studies. Our highly qualified clinical investigators conducted these studies.
- Recruit participants from the T1D Exchange Clinic Registry to participate in clinical studies.
Collaborating for Improved Outcomes: A Case Study
The potential of bringing intranasal glucagon to market to relieve the burden of severe hypoglycemia has been a case study in partnership and collaboration, including:
- Initial funding from The Leona M. and Harry B. Helmsley Charitable Trust and Locemia Solutions
- Real-world evidence about complexities of the glucagon rescue kit from the Glu community.
- T1D Exchange works with Locemia Solutions to design and run phase III clinical studies and recruits participants from its Clinic Registry
- Lilly is now leveraging its global expertise and heritage in diabetes to bring this product to market.
Read more about this announcement from Lilly.
Background on Severe Hypo and Intranasal Glucagon
In type 1 diabetes, a severe low can cause confusion, seizures, or unconsciousness. It requires medical intervention right away from someone other than the person with T1D. It might be a spouse, parent, or friend. It can be a teacher, coach, or babysitter—most often, it’s from someone who has no medical training.
Today’s life-saving hypoglycemia rescue kit is complex. It contains a powdered form of glucagon that needs to be reconstituted into a liquid, drawn into a needle and injected in the person’s thigh. No easy task under the best of circumstances—and certainly not while a loved one or friend is seizing or unconscious.
Intranasal glucagon could be the first needle-free rescue treatment for severe hypoglycemia.
Intranasal glucagon uses a proprietary glucagon nasal powder formulation that is delivered in an emergency situation using a single-use, ready-to-use device. The caregiver presses a small plunger on the bottom of the device to release the glucagon as a puff in the nose, where the glucagon is absorbed in the nasal passages.
Congratulations to our members, Lilly and Locemia Solutions, and to the entire T1D Exchange patient community!
—Dana Ball
Co-founder and Executive Director, T1D Exchange
Co-founder and Executive Director, T1D Exchange
Sem comentários:
Enviar um comentário